Tag:

Reckitt Benckiser

Latest Headlines

Latest Headlines

Reckitt CFO: Spinoff of pharma unit a 'strong option'

British consumer products maker Reckitt Benckiser said during a first-quarter business review today that it's moving closer to carving out its struggling pharmaceutical unit and listing it as a separate public company. A strategic review of the unit that was launched last October continues, but a "capital markets solution is emerging as a strong option," Reckitt CFO Adrian Hennah told Reuters.

Reckitt may top Novartis, Sanofi in $12B race for Merck consumer unit

With a final bid deadline looming, Merck & Co.'s consumer health unit still has several big-name pharma suitors. But Reckitt Benckiser, the Irish consumer specialist, may end up snatching the prize, Bloomberg reports.

Sanofi reportedly jumps into $12B race for Merck's consumer unit

Sanofi CEO Chris Viehbacher may be reconsidering his November plans to spend just €1 billion to €2 billion per year on acquisitions. Rumor has it the drug giant is eyeing a bid for Merck's OTC unit, which could sell for up to $12 billion.

Reckitt hires a pharma chairman, stoking talk of a spinoff

Nothing makes analysts happier these days than a prospective spinoff. And with a new chairman stepping in to help conduct the ongoing strategic review of the struggling Reckitt Benckiser pharma unit, some say one could be on the way for the British group.

French competition watchdog slaps Merck, Reckitt for talking down Subutex generics

European antitrust watchdogs have struck again. As Reuters reports, France's competition authority has fined Merck's Schering-Plough unit €15.3 million ($21 million) for a "smear campaign" against generic competitors to Subutex, a drug for opioid addication.

Feds seize documents from Reckitt Benckiser pharma

Federal agents reportedly carried boxes of documents out of the Reckitt Benckiser headquarters in Virginia on Tuesday. The officials did not disclose the purpose of the warrant.

Does Reckitt's drug business make a match with Shire?

We know Reckitt Benckiser is shopping its pharma unit. We also know that Shire is scouting for deals. Does it follow that Shire may bid on RB Pharma? Logically, yes. Practically? Maybe.

Reckitt weighs pharma-unit sale as Suboxone slumps

Reckitt Benckiser has said the time to weigh options for its pharmaceuticals unit would come after its flagship drug, Suboxone, fell victim to generic competition. That time is now. The British consumer goods group says it's reviewing options for its pharma business, including a possible sale that could grab upwards of $3.2 billion.

Reckitt bid to block Suboxone copies fails

The U.K.-based company had petitioned the agency to block the copycat versions on packaging grounds.

Bristol licenses OTC brands to Reckitt for 'eye-watering' $482M

Reckitt Benckiser has nabbed Latin American rights to a basket of Bristol-Myers Squibb's ($BMY) over-the-counter products for a cool $482 million.